Is haemophilia B less severe than haemophilia A?

Haemophilia

Volumn 19, Issue 4, 2013, Pages 499-502

  Mannucci, P M ^a   Franchini, M ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

Author keywords

Bleeding; Haemophilia A; Haemophilia B; Therapy

Indexed keywords

BLOOD CLOTTING FACTOR 9;

ARTHROPLASTY; CAUSE OF DEATH; COMPARATIVE STUDY; DISEASE SEVERITY; GENE MUTATION; HEMOPHILIA A; HEMOPHILIA B; HOSPITAL ADMISSION; HUMAN; PRIORITY JOURNAL; REVIEW; SUBSTITUTION THERAPY; SURGICAL RISK;

BLOOD COAGULATION FACTORS; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MUTATION; ORTHOPEDICS;

EID: 84879464259     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12133     Document Type: Review

References (31)

1. Mannucci PM, Tuddenham EGD. The hemophiliacs - from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
2. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012; 379: 1447-56.
3. White GC II, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
4. Jayandharan GR, Srivastava A. The phenotypic heterogeneity of severe hemophilia. Semin Thromb Hemost 2008; 34: 128-42.
5. Hoyer LH. Hemophilia A. N Engl J Med 1994; 330: 38-47.
6. Franchini M, Frattini F, Crestani S, Bonfanti C. Hemophilia B: current pharmacotherapy and future directions. Expert Opin Pharmacother 2012; 13: 2053-63.
7. Makris M. Is VIII worse than IX? Blood 2009; 114: 750-1.
8. Lowe GD, Ludlam CA. Less severe bleeding in hemophilia B than in hemophilia A. J Thromb Haemost 2008; 6: 1982-3.
9. Tagariello G, Iorio A, Santagostino E et al. Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood 2009; 114: 779-84.
10. Quick AJ, Hussey CV. Hemophilia B (PTC deficiency, or Christmas disease). Arch Intern Med 1959; 103: 762-75.
11. Pai KM, Walker I, Almonte T, Chan AK, Sek J, Decker K. Comparing bleed frequency and factor concentrate use between haemophilia A and haemophilia B. J Thromb Haemost 2005; 3(Suppl. 1): P0807. Abstr.
12. Nagel K, Walker I, Decker K, Chan HKC, Pai MK. Comparing bleed frequency and factor concentrate use between haemophilia A and haemophilia B. Haemophilia 2011; 17: 872-4.
13. Biss TT, Chan AK, Blanchette VS, the association of hemophilia clinic directors of Canada (AHCDC) and the Canadian association of nurses in hemophilia care (CANHC) et al. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia 2008; 14: 923-30.
14. Klamroth R, Orlovic M, Kubicek-Hofman C, Hamophilie Gottstein S. A und Hamophilie B. Hamostaseologie 2010; 30(Suppl. 1): S26-7.
15. Shulman S, Eelde A, Holmstrom M, Stahlberg G, Odeberg J, Blombacks M. Validation of a composite score for clinical severity of hemophilia. J Thromb Haemost 2008; 6: 1113-21.
16. Tagliaferri A, Di Perna C, Franchini M, Rivolta GF, Pattacini C. Hemophilia severity score system: validation from an Italian Regional Reference Center. J Thromb Haemost 2009; 7: 720-2.
17. Ludlam CA, Lee RJ, Prescott RJ et al. Haemophilia care in Central Scotland 1980-94. I. Demographic characteristics, hospital admissions and causes of death. Haemophilia 2000; 6: 494-503.
18. F8 HAMSTeRS mutation database. Available at http://europium.csc.mrc.ac.uk. Accessed November 15, 2012.
19. F9 mutation database. Available at http://www.kcl.ac.uk/ip/petergreen/haemB-database.html. Accessed November 15, 2012.
20. Margaglione M, Castaman G, Morfini M et al. The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica 2008; 93: 722-8.
21. Belvini D, Salviato R, Radossi P et al. Molecular genotyping of the Italian cohort of patients with hemophilia B. Haematologica 2005; 90: 635-42.
22. Green PM, Bagnall RD, Waseem NH, Giannelli F. Haemophilia A mutations in the UK: results of screening one-third of the population. Br J Haematol 2008; 143: 115-28.
23. Siegemund T, Petros S, Siegemund A et al. Thrombin generation in severe hemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. Thromb Haemost 2003; 90: 781-6.
24. Dargaud Y, Beguin S, Lienhart A et al. Evaluation of thrombin generation capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93: 475-80.
25. Santagostino E, Mancuso ME, Tripodi A et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost 2010; 8: 737-43.
26. Biggs R, MacFarlane RG eds. Treatment of Haemophilia and Other Coagulation Disorders. Oxford: Blackwell Scientific Publications, 1966: 27-29.
27. den Uijl IEM, Rosendaal G, Fischer K. Insufficient evidence to suggest less stringent therapy in hemophilia B? Blood 2009; 114: 4907-8.
28. Peters RT, Low SC, Kamphaus GD et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010; 115: 2057-64.
29. Negrier C, Knobe K, Tiede A, Giangrande P et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118: 2695-701.
30. Shapiro AD, Ragni MV, Valentino LA et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012; 119: 666-72.
31. Santagostino E, Negrier C, Klamroth R et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120: 2405-11.